Benefit assessment in Germany: implications for price discounts

BACKGROUND: The AMNOG regulation, introduced in 2011 in Germany, changed the game for new drugs. Now, the industry is required to submit a dossier to the GBA (the central decision body in the German sickness fund system) to show additional benefit. After granting the magnitude of the additional bene...

Descripción completa

Detalles Bibliográficos
Autores principales: Theidel, Ulrike, von der Schulenburg, J-Matthias Graf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970987/
https://www.ncbi.nlm.nih.gov/pubmed/27485438
http://dx.doi.org/10.1186/s13561-016-0109-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970987/
https://www.ncbi.nlm.nih.gov/pubmed/27485438
http://dx.doi.org/10.1186/s13561-016-0109-3

Ejemplares similares